文献速递外周动脉疾病

慢性肢体威胁性缺血患者对侧肢体的疾病进展

Progression of the contralateral limb in chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2025-02-04

单中心回顾性队列纳入439例初诊单侧慢性肢体威胁性缺血(CLTI)患者,中位随访24个月时36.4%发生对侧CLTI。低基线对侧趾臂指数(TBI)与终末期肾病(ESRD)为独立危险因素,对侧CLTI与更差的无截肢生存相关。

要点

  • 单侧CLTI患者中位24个月时36.4%进展为对侧CLTI。
  • 低基线对侧TBI(HR 0.18)与ESRD(HR 1.95)为独立危险因素。
  • 发生对侧CLTI者无截肢生存期更短(70.9 vs 85.3个月,P<.001)。

核心结论

  • 初诊后中位24个月内超过三分之一的CLTI患者发生对侧CLTI,且与更差结局相关;ESRD与低初始对侧TBI患者对侧疾病进展风险尤其高,这些发现有助于确定对侧CLTI患者的监测间隔并识别最高危人群。

研究设计与样本

  • 单中心回顾性队列研究,纳入439例单侧CLTI患者(63.1%男性;中位年龄69岁,四分位距62-77岁),收集合并症、WIfI分级/临床分期及结局数据,采用单因素与Cox回归及Kaplan-Meier生存分析。

主要发现

  • 中位24个月(四分位距10-55个月)时36.4%患者发生对侧CLTI。
  • 单因素分析显示对侧CLTI与黑人种族(P=.037)、糖尿病(P<.001)、神经病变(P<.001)、视网膜病变(P=.002)、慢性肾脏病(P<.001)、终末期肾病(P<.001)、冠状动脉旁路移植术史(P=.01)及较低基线对侧TBI(P<.001)相关。
  • 多变量Cox回归显示低基线对侧TBI(HR 0.18;95%CI 0.07-0.43;P<.001)与ESRD(HR 1.95;95%CI 1.26-2.99;P=.003)为对侧CLTI发生的独立危险因素。
  • 对侧CLTI患者原患肢组织丢失更严重、伤口评分更高(WIfI-W2)且疾病分期更晚(WIfI-4期:52.9% vs 37.9%;P=.003)。
  • 对侧CLTI患者原患肢大截肢率更高(43.3% vs 12.0%;P<.001),对侧肢大截肢率为22.0%;无截肢生存期更短(70.9个月;95%CI 58.9-82.8个月 vs 85.3个月;95%CI 76.8-93.9个月;P<.001);两组死亡率相似(单侧组16.0% vs 对侧组20.7%;P=.21)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: For patients initially presenting with unilateral chronic limb-threatening ischemia (CLTI), the progression and natural history of the contralateral limb (CL) remain underexplored, and current guidelines provide insufficient guidance for monitoring progression and managing contralateral disease. This study aims to evaluate the prevalence, risk factors, and outcomes associated with the development of contralateral CLTI (CL-CLTI) in patients initially diagnosed with unilateral CLTI. METHODS: This was a single-center, retrospective cohort study including patients with unilateral CLTI. Data on comorbidities, Wound, Ischemia, and Foot Infection (WIfI) grades/clinical stages, and outcomes were collected. Statistical analyses included univariate and Cox regression, as well as Kaplan-Meier survival estimates where appropriate. RESULTS: Over a 9-year period, 439 patients with unilateral CLTI were included in the analysis (63.1% male; median age, 69 years; interquartile range, 62-77 years). CL-CLTI developed in 36.4% of patients at a median of 24 months (interquartile range, 10-55 months). Univariate analysis revealed significant associations between CL-CLTI and Black race (P = .037), diabetes (P < .001), neuropathy (P < .001), retinopathy (P = .002), chronic kidney disease (P < .001), end-stage renal disease (ESRD) (P < .001), history of coronary artery bypass grafting (P = .01), and lower baseline contralateral leg toe-brachial index (TBI) (P < .001). Multivariable Cox regression identified low baseline contralateral TBI (hazard ratio, 0.18; 95% confidence interval [CI], 0.07-0.43; P < .001) and ESRD (hazard ratio, 1.95; 95% CI, 1.26-2.99; P = .003) as independent risk factors for CL-CLTI development. Patients with CL-CLTI exhibited more severe tissue loss in the index leg, higher wound scores (WIfI-W2), and more advanced disease stages (WIfI-Stage 4, 52.9% vs 37.9%; P = .003) compared with unilateral patients. During follow-up, patients with CL-CLTI experienced significantly higher rates of major amputations in both the index leg (43.3% vs 12.0%; P < .001) and the contralateral leg (22.0%). Kaplan-Meier analysis showed significantly reduced amputation-free survival in patients with CL-CLTI (70.9 months; 95% CI, 58.9-82.8 months) compared with those with unilateral disease (85.3 months; 95% CI, 76.8-93.9 months; P < .001). Mortality rates were similar between groups (unilateral: 16.0%, contralateral: 20.7%; P = .21). CONCLUSIONS: Within a median of 24 months of initial presentation, over one-third of patients with CLTI develop CL-CLTI, which is associated with worse outcomes. Patients with ESRD and low initial contralateral TBI are at particularly high risk for contralateral disease progression. These findings help to define appropriate monitoring intervals for patients with CL-CLTI and identify those at highest risk of disease progression.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Koksoy C, Torres Ruiz I, Pallister ZS, et al. Progression of the contralateral limb in chronic limb-threatening ischemia. J Vasc Surg. 2025. PMID: 39909214. doi:10.1016/j.jvs.2025.01.207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。